Research Article
Association between Phenotypic Age and Mortality in Patients with Multivessel Coronary Artery Disease
Table 1
Characteristics of the study participants.
| | Characteristics | No. (%) or |
| | All | 609 | | Chronological age (y) | | | Men, (%) | 506 (83.1) | | Body mass index, kg/m2 | | | Current smoker, (%) | 298 (48.9) | | Drinking, (%) | 132 (21.7) | | Physician-diagnosed diseases | | | Hypertension | 342 (56.2) | | Type 2 diabetes | 224 (36.8) | | Stroke | 61 (10.0) | | Chronic kidney disease | 46 (7.6) | | CAD | 609 (100) | | Disease count, (%) | | | 1 | 173 (28.4) | | 2 | 240 (39.4) | | 3+ | 196 (32.2) | | Oral medications, (%) | | | Antiplatelet drugs | 475 (78.0) | | Statins | 371 (60.9) | | Beta-blockers | 319 (52.4) | | ACEI/ARB | 165 (27.1) | | Calcium channel blocker | 130 (21.3) | | Nitrate | 65 (10.7) | | Preoperative laboratory measurements | | | Hemoglobin (g/L) | | | Red cell distribution width (%) | | | White blood cell (109/L) | | | Lymphocyte percent (%) | | | Mean cell volume (fL) | | | Albumin (mg/dL) | | | Glucose (mmol/L) | | | Serum uric acid (μmol/L) | | | Creatinine (μmol/L) | | | Alkaline phosphatase (U/L) | | | Total cholesterol (mmol/L) | | | Total triglycerides (mmol/L) | | | Low-density lipoprotein cholesterol (mmol/L) | | | High-density lipoprotein cholesterol (mmol/L) | | | C-reactive protein (mg/dL) | 0.4 (0.3, 0.8) | | Creatine kinase (U/L) | 73 (57, 105) | | Creatine phosphokinase isoenzyme (U/L) | 12 (9, 16) | | N-terminal probrain natriuretic peptide (pg/mL) | 355 (150, 1085) | | PhenoAge (y) | | | PhenoAgeAccel (y) | -1.7 (-5.0, 4.5) | | PhenoAgeAccel subgroups | | | Negative, (%) | 355 (58.3) | | Positive, (%) | 254 (41.7) | | Angiographic and procedural characteristics | | | Number of diseased vessels, (%) | | | 2 | 117 (19.2) | | 3 | 492 (80.8) | | Procedural success, (%) | 336 (55.2) | | Clinical outcomes on follow-up | | | All-cause mortality, (%) | 62 (10.2) | | Cardiac mortality, (%) | 32 (5.3) | | Others, (%) | 30 (4.9) |
|
|
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; PhenoAge: Phenotypic Age; PhenoAgeAccel: phenotypic age acceleration.
|
